Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 173

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 5
Chunk 173
---
 incurred operating losses resulting in carryforward tax losses totaling approximately $218 million as of December 31, 2024, to be carried forward indefinitely to future tax years. Accordingly, we do not expect to pay taxes in Israel for the foreseeable future, until we have taxable income after the full utilization of our carryforward tax losses.
 
Our U.S. subsidiaries, Evogene Inc., Lavie Bio Inc., Lavie Bio Tech Inc., Taxon Biosciences Inc. and AgPlenus Inc. are subject to U.S. income taxes. In 2024, the tax rates applicable to those companies were approximately 21% and 3.41% (federal tax and state tax, respectively, where those companies operate).
 
Segment Data
 
We divide our operations into three operating segments – agriculture, human health and industrial applications, as follows:
 

◾                     Agriculture: our agriculture segment includes our division and subsidiaries engaged in agricultural                   
    activities, including seed traits activity, ag-chemicals activity (now through our subsidiary AgPlenus) and ag-biologicals activity (now
                                                       through our subsidiary Lavie Bio).                                                   
--------------------------------------------------------------------------------------------------------------------------------------------

◾   Human Health: our human health segment focuses mainly on discovery and development of human
                  microbiome-based therapeutics (through our subsidiary Biomica).              
-----------------------------------------------------------------------------------------------

◾        Industrial Applications: our industrial applications segment focuses on the development and      
    commercialization of improved castor bean seeds for industrial uses (through our subsidiary Casterra).
----------------------------------------------------------------------------------------------------------
 

The following table presents our revenues and operating loss by segment for the periods presented:
 

                                Agriculture             Industrial Applications              Human Health             Unallocated               Total       
------------------------------------------------------------------------------------------------------------------------------------------------------------
                               (U.S. dollars, in thousands)                                                                                                 
Year ended December 31, 2024                                                                                                                                
Revenues                       $5,889                  $2,219                              $80                       $323                    $8,511         
Operating loss                 $(9,262         )       $(2,411                     )       $(7,240           )       $(3,297         )       $(22,210      )
Year ended December 31, 2023                                                                                                                                
Revenues                       $3,791                  $1,075                              $487                      $287                    $5,640         
Operating loss                 $(11,100        )       $(39                        )       $(10,349          )       $(5,020         )       $(26,508      )
Year ended December 31, 2022                                                                                                                                
Revenues